Yung Zip Chemical Ind. Co., Ltd. · TPEX:4102
Yung Zip Chemical Ind — 2023 Investors Relations Conference
21 slides from Yung Zip Chemical Ind's conference presentation, Sep 21, 2023
Slide 1: 2023 Investors Relations Conference
Stock Code：4102 2023 Investors Relations Conference Sep. 21, 2023
Slide 2: Disclaimer
Disclaimer The forward-looking statements and related information made in this presentation ,which may include YZC’ future results of operations, financial condition or business prospects are obtained by YZC through internal and external sources. These forward-looking statements involve known and un
Slide 3: Contents
CONTENTS Company Introduction Financial Performance Overview Business Development Research and Development Strategy 2/20
Slide 4: Company Introduction: Philosophy
Company Introduction: Philosophy Vision: Dedicated to avoiding human diseases business Yung Zip Chemical Ind. Co., Ltd. established on June 8, 1978. As the first executor of GMP API production in Taiwan, Yung Zip has successively obtained international certifications which are from FDA, MHRA, PMDA,
Slide 5: R&D Technology Application and Business Development
R&D Technology Application and Business Development Drugs registration Speciality TDMF ：16 APIs Chemical US DMF：18 Optoelectronic/ EU CEP：3 JP MF：3 Synthesis Technique Plasticizing/ Other countries：16 Semiconductor GMP approved Small-scale Test TFDA：18 Pilot Plant Material U.S. FDA：5 G
Slide 6: Contents
CONTENTS Company Introduction Financial Performance Overview Business Development Research and Development Strategy 5/20
Slide 7: Statement of Consolidated Comprehensive Income
Statement of Consolidated Comprehensive Income Items 2023 H1 2022 H1 YoY (In Thousands of New Taiwan Dollars) (Reviewed) (Reviewed) Operating Revenue 272,601 262,792 4% Operating costs 189,191 187,029 1% Gross Profit 83,410 75,763 10% Gross Margin 30% 29% Operating Expenses 57,932 55,938 4% Operatin
Slide 8: Consolidated Balance Sheet
Consolidated Balance Sheet Items 2023/6/30 2022/6/30 2021/6/30 (In Thousands of New Taiwan Dollars) (Reviewed) (Reviewed) (Reviewed) Cash and Cash Equivalents 156,674 15% 122,282 13% 49,023 5% Receivables 120,299 12% 139,624 14% 129,774 14% Inventories 153,496 15% 139,980 14% 170,401 18% Long-term I
Slide 9: Consolidated Cash Flow
Consolidated Cash Flow 2023 H1 2022 H1 2021 H1 (In Thousands of New Taiwan Dollars) (Reviewed) (Reviewed) (Reviewed) Cash and cash equivalents at beginning of period 144,179 78,200 53,406 Cash flows from operating activities 58,979 22,984 15,521 Cash flows from investment activities (5,390) 32,276 (
Slide 10: Contents
CONTENTS Company Introduction Financial Performance Overview Business Development Research and Development Strategy 9/20
Slide 11: Jan.-Sep. Operating Revenue (2022 VS 2023)
Jan.-Sep. Operating Revenue (2022 VS 2023) (In Thousands of New Taiwan Dollars) 400,000 351,646 357,049 350,000 Sales Distribution 300,000 217,905 EXPORT 256,612 250,000 139,144 DOMESTIC 200,000 95,034 - 100,000 200,000 300,000 150,000 Jan. - Aug. 2023 Jan. - Aug. 2022 100,000 50,000 01-08/'22 01-08
Slide 12: Globe Market distribution
Globe Market distribution Period: Jan. – Aug. of 2022/2023 Jan.-Aug. 2022 Jan.-Aug. 2023 America Europe America Europe 8% 2% 8% 3% Africa Taiwan Africa 2% 27% 3% Taiwan 39% Asia Asia 47% 61% Jan.-Aug. 2022 Jan.-Aug. 2023 Difference Taiwan 27% 39% 12% Asia 61% 47% -15% Africa 2% 3% 1% America 8% 8% 0
Slide 13: Growth of Asian Market Distribution
Growth of Asian Market Distribution Period: Jan. – Aug. of 2022/2023 (In Thousands of New Taiwan Dollars) 60,000 10% 50,000 39% 40,000 30,000 55% 20,000 50% 10,000 NEW NEW 0 Speciality EDV CLD MCN3 SSG7 MFA Chemicals Jan.-Aug. 2022 Jan.-Aug. 2023 12/20
Slide 14: 2016-2022 Consolidated Revenue
2016-2022 Consolidated Revenue (In Thousands of New Taiwan Dollars) 600,000 4,255 500,000 13,257 400,000 40,122 318,597 9,793 259,802 300,000 289,528 284,896 200,000 271,259 190,897 265,391 91,988 122,879 79,937 100,000 60,215 29,037 28,116 27,806 33,810 1,917 56,210 92,562 49,077 47,061 48,233 58,0
Slide 15: Industry Overview
Industry Overview GLOBE • The global supply chain has faced great challenges from previous inflation, supply chain conformity, and epidemics. Over-concentration on purchasing pharmaceutical raw materials from one single country will turn out to be a possible drug shortage crisis. Therefore, many cou
Slide 16: Contents
CONTENTS Company Introduction Financial Performance Overview Business Development Research and Development Strategy 15/20
Slide 17: Research and Development Strategy: Five Main Strategies
Research and Development Strategy FIVE MAIN STRATEGY Current process optimization Development Expand Development Development of APIs of clinical new CDMO&CMO of Speciality And ESG process Chemical drug business development • Improve the • Explore the products • Cooperate • Increase the • Open up the
Slide 18: New Product Development
New Product Development API *Source: Cortellis™ Generics Intelligence Data *Global market *Global market Progress Product Indication Target market scale scale (USD) (kg) Amyotrophic lateral EDV US 532 M 817.2 sclerosis Process Validation MRG Overactive bladder JP/US 3,142 M 50,078 Completed (Custo
Slide 19: Speciality Chemicals Development Plan
Speciality Chemicals Development Plan Speciality Chemicals Quantity Progress Product Indication Area (Kg)/year TX06 Speciality chemical TW/JP 240 Process Development Completed (Make-to-order period) TX07 Speciality chemical TW/JP 2,000 Process Development TX04 Speciality chemical TW/JP 500~1,000 C
Slide 20: Thank you for your attention!
Thank you for your attention ! 19/20
Slide 21: Q&A
Ｑ&A 20/20
Yung Zip Chemical Ind. — 2023 Investors Relations Conference on 6ix